Starbucks wins dismissal of shareholder fraud lawsuit in U.S. and China

A federal judge dismissed a shareholder lawsuit against Starbucks alleging it defrauded investors by concealing declining U.S. and China sales, ruling the CEO’s January 2024 statements had an “innocent explanation.” The legal news follows Starbucks’ sharp stock drop of 16% on May 1, 2024, tied to a lowered annual sales forecast, with latest-quarter same-store sales down 4.4% (U.S. -3%, China -11%). The dismissed case slightly reduces litigation risk, but the underlying demand deterioration and forecast cut remain near-term headwinds for SBUX as management pursues its “Back to Starbucks” turnaround.

Analysis

For SBUX, the legal dismissal removes a headline overhang but does not change the core underwriting variable: traffic and mix recovery. In market terms, this is worth a modest multiple de-risking, not an earnings rerate; if the turnaround fails to show up in the next 1-2 quarters, any relief rally should fade because investors will re-anchor on same-store sales and labor/productivity execution. The true upside is that a cleaner litigation tape can lower implied volatility, making short-dated option selling more attractive after strength.

The second-order dynamic is that the stock may now trade more like a turnaround-quality compounder than a litigation story, which raises the bar for management to prove sequencing on menu simplification, speed, and store rationalization. If those steps create near-term friction, the market could punish SBUX for slower traffic even as the legal cloud clears. A move above recent resistance without evidence of comp inflection would be vulnerable.

For TSM, the relevant signal is not the beat itself but the capex intensity implied by the spending plan. That typically shifts the trade from TSM toward the equipment complex: AMAT, LRCX, and ASML are better positioned to capture incremental WFE dollars, while TSM may see margin/FCF pressure if capex outruns revenue growth over the next 6-12 months. Contrarian risk: the market may be too focused on near-term free cash flow and underestimating that elevated capex is a read-through for sustained AI/leading-edge demand, not just cost inflation.

Key Decisions for Investors

• Do not chase SBUX on the dismissal headline; if the stock gaps up >3%, consider a 1-2 month call-credit or put-spread fade, because the next real catalyst is comp data, not litigation.
• Pair trade: long MCD / short SBUX over the next 1-3 months to express relative quality versus turnaround risk; thesis fails if SBUX posts sequential U.S. traffic improvement and China stabilizes.
• Use any TSM weakness to add AMAT or LRCX on a 1-3 month horizon; higher capex is a cleaner earnings tailwind for semicap than for TSM’s own multiple.
• Set an alert on SBUX next quarterly same-store-sales print; if U.S. comps remain negative and China does not inflect, treat the legal ruling as non-catalytic and exit any bullish exposure.
• For TSM, watch gross margin and FCF guidance rather than headline EPS; if capex rises while margin guidance stays flat, expect multiple compression and favor supplier exposure instead.